Published in Mol Cell Biol on January 01, 1995
A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol (1996) 5.75
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol (1996) 1.98
The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med (1996) 1.94
Having it both ways: transcription factors that bind DNA and RNA. Nucleic Acids Res (2002) 1.84
Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A (1997) 1.73
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A (1995) 1.52
Interaction of p53 with the human Rad51 protein. Nucleic Acids Res (1997) 1.43
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci U S A (1999) 1.33
The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci U S A (1995) 1.22
p53 binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. Mol Cell Biol (2000) 1.22
Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein. J Virol (1999) 1.16
Cytoplasmic p53 polypeptide is associated with ribosomes. Mol Cell Biol (1997) 1.12
p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol (1998) 0.95
The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res (1997) 0.93
p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol (2004) 0.93
Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system. RNA (2006) 0.91
Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc Natl Acad Sci U S A (1997) 0.91
Dominant genetic screen for cofactors that enhance antisense RNA-mediated gene silencing in fission yeast. Nucleic Acids Res (2002) 0.90
p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene (2015) 0.88
Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res (2000) 0.85
Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases. Nucleic Acids Res (2002) 0.85
Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One (2009) 0.83
Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Nucleic Acids Res (1995) 0.82
The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol (1997) 0.82
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Front Oncol (2015) 0.79
Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. Biochem J (1996) 0.79
DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs. Nucleic Acids Res (1997) 0.79
p53-mediated DNA renaturation can mimic strand exchange. Nucleic Acids Res (1997) 0.78
Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Res (2001) 0.78
Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions. EMBO Rep (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol (1981) 15.59
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
Wild-type p53 activates transcription in vitro. Nature (1992) 11.39
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell (1992) 7.06
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 6.03
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol (1984) 4.83
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev (1993) 3.99
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A (1990) 2.77
p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev (1993) 2.74
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene (1992) 2.41
Purification of complexes of nuclear oncogene p53 with rat and Escherichia coli heat shock proteins: in vitro dissociation of hsc70 and dnaK from murine p53 by ATP. Mol Cell Biol (1988) 2.25
p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J (1993) 2.16
p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A (1994) 1.74
Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol Cell Biol (1985) 1.72
A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene (1987) 1.62
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene (1990) 1.59
A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc Natl Acad Sci U S A (1992) 1.16
Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res (1992) 1.10
Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol (1994) 1.08
Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ (1991) 1.05
The sequence of the human genome. Science (2001) 101.55
Surfing the p53 network. Nature (2000) 35.36
Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell (2000) 7.82
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 6.67
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 5.73
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science (1999) 5.72
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature (2000) 4.52
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50
DNA replication in SV40 infected cells. I. Analysis of replicating SV40 DNA. J Mol Biol (1970) 4.49
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science (1999) 4.21
Gain of function mutations in p53. Nat Genet (1993) 4.19
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol (1985) 4.03
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99
The process of infection with bacteriophage phiX174. XXV. Studies with bacteriophage phiX174 mutants blocked in progeny replicative form DNA synthesis. J Mol Biol (1969) 3.87
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol (1996) 3.81
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 3.56
Isolation and characterization of polyoma host range mutants that replicate in nullipotential embryonal carcinoma cells. Proc Natl Acad Sci U S A (1981) 3.55
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev (1999) 3.41
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (1995) 3.39
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol (1998) 3.38
Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells. J Virol (1984) 3.38
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology (1979) 3.33
DNA-binding proteins specific for cells infected by adenovirus. Nat New Biol (1973) 3.30
Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev (2000) 3.30
Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis. J Virol (1975) 3.29
A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (1997) 3.29
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol (1986) 3.04
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol (1987) 3.01
Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature (1998) 3.01
Conversion of the lac repressor into an allosterically regulated transcriptional activator for mammalian cells. Mol Cell Biol (1990) 3.00
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76
Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev (1999) 2.73
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology (1983) 2.69
WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev (2000) 2.67
A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells. Virology (1982) 2.65
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol (1986) 2.64
Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A (2001) 2.55
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature (1998) 2.52
A comparison of the biological activities of wild-type and mutant p53. FASEB J (1993) 2.49
Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48
The p53 functional circuit. J Cell Sci (2001) 2.46
Mechanism by which fiber antigen inhibits multiplication of type 5 adenovirus. J Virol (1967) 2.44
Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J (1997) 2.44
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Structure of the histone deacetylase SIRT2. Nat Struct Biol (2001) 2.37
Identification and characterization of an immunologically conserved adenovirus early region 11,000 Mr protein and its association with the nuclear matrix. J Mol Biol (1982) 2.36
Induced alpha helix in the VP16 activation domain upon binding to a human TAF. Science (1997) 2.35
A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl beta-D-thiogalactopyranoside. Proc Natl Acad Sci U S A (1991) 2.35
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Deoxyribonucleic acid replication in simian virus 40-infected cells. II. Detection and characterization of simian virus 40 pseudovirions. J Virol (1970) 2.30
DNA replication in SV40-infected cells. IX. The inhibition of a gap-filling step during discontinuous synthesis of SV40 DNA. Virology (1973) 2.27
Purification of complexes of nuclear oncogene p53 with rat and Escherichia coli heat shock proteins: in vitro dissociation of hsc70 and dnaK from murine p53 by ATP. Mol Cell Biol (1988) 2.25
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell (1990) 2.20